Contents

Geriatric PharmacologyEdit

Geriatric pharmacology is the medical science of how aging alters the way medicines behave in the body and how best to use drugs to maintain health, function, and independence in older adults. It integrates pharmacokinetics (what the body does to a drug) and pharmacodynamics (what a drug does to the body) with considerations of multiple chronic conditions, functional status, medication burden, and the realistic goals of care. As populations age, treating older patients effectively while minimizing harm has become a central concern of modern clinical practice, research, and health policy. This field also grapples with gaps in the evidence base, since older adults—especially those with frailty, multimorbidity, or cognitive impairment—are often underrepresented in randomized trials, which can complicate guideline development and individual decision-making. Aging Geriatrics Pharmacology

Pharmacokinetics in aging

Aging brings predictable physiological changes that influence drug absorption, distribution, metabolism, and excretion. Understanding these shifts helps clinicians tailor dosing and monitoring to reduce adverse outcomes.

  • Absorption

    • Gastric acidity and motility commonly decline with age, altering the rate (and, for some drugs, the extent) of oral absorption. Transdermal, subcutaneous, and intravenous routes may offer more predictable absorption for certain medications in some patients. These changes are considered in light of each drug’s formulation and bioavailability. See for example discussions of Pharmacokinetics and the practical implications for common medications.

  • Distribution

    • Body composition shifts: increased fat mass and decreased lean body mass and total body water. Plasma protein levels, such as albumin, can influence protein binding for highly bound drugs, potentially increasing the free, active fraction in some cases. These distribution changes can affect both efficacy and toxicity of drugs with narrow therapeutic windows. See Pharmacokinetics for related concepts.

  • Metabolism

    • Hepatic blood flow and enzyme activity often decline with age, especially for certain Phase I metabolic pathways. This can slow clearance for many drugs, extending half-lives and increasing the risk of accumulation if dosing intervals are not adjusted. Phase II processes may be relatively preserved, but individual variability remains high. Clinicians weigh these factors alongside concomitant illnesses and medications. See Liver and Metabolism entries for broader context.

  • Renal elimination

    • Renal function typically declines with aging, even in the absence of overt kidney disease. Decreased glomerular filtration rate (GFR) necessitates dose adjustments for many renally excreted drugs. Clinicians often estimate renal function using formulas such as the Cockcroft-Gault method or the newer CKD-EPI, and they monitor drug levels or responses as appropriate. See Renal function and eGFR for related material.

Pharmacodynamics in aging

In addition to how the body handles drugs, aging can alter sensitivity to medications. Receptor density, signal transduction, and homeostatic regulatory mechanisms may change, affecting both therapeutic effects and adverse effects.

  • Receptor and homeostatic changes

    • Increased sensitivity to central nervous system depressants (for example, sedative and anticholinergic medications) and altered cardiovascular reflexes can raise the risk of falls, delirium, orthostatic intolerance, and cognitive impairment in older patients. These dynamics underscore the importance of starting with lower doses and titrating cautiously. See Pharmacodynamics for foundational concepts.

  • Clinical implications

    • The same dose may produce different effects in an older patient compared with a younger one. Clinicians integrate pharmacodynamic changes with goals of care, functional status, and risk/benefit considerations. See discussions of Beers Criteria and START/STOPP criteria as practical tools used in this context.

Polypharmacy, deprescribing, and guidelines

Many older adults take multiple medications for several chronic conditions. While appropriate therapy is essential, polypharmacy raises the risk of adverse drug events, drug–drug interactions, cognitive effects, and decreased adherence. A careful, individualized approach aims to maximize benefit while minimizing harm.

  • Polypharmacy

    • The coexistence of multiple medications increases the potential for interactions and confusion in dosing, monitoring, and adherence. Tools and processes for medication review are central to improving safety. See Polypharmacy and Medication review discussions for broader context.

  • Deprescribing

    • Deprescribing is the planned reduction or cessation of medications when risks outweigh benefits, a process that should be patient-centered and evidence-informed. It involves shared decision‑making, monitoring for withdrawal or recurrence of symptoms, and alignment with patient goals. See Deprescribing.

  • Guidelines and criteria

    • Beers Criteria and START/STOPP criteria are widely used in geriatric prescribing to identify potentially inappropriate medications and opportunities for optimization. These guidelines help clinicians balance safety with the need to manage chronic diseases. See Beers Criteria and START/STOPP criteria for more detail.

  • Evidence base

    • Guidelines increasingly emphasize real-world outcomes, functional status, and patient preferences. The interplay between guideline recommendations and individual goals can be complex, especially in frail or cognitively impaired patients. See Clinical guidelines and Geriatric assessment for related topics.

Drug safety, monitoring, and common concerns

Older adults face a heightened risk of adverse drug events (ADEs) and functional decline from medications. Proactive monitoring and tailored regimens are essential.

  • Common ADEs and risks

    • Falls, orthostatic hypotension, delirium, constipation, bleeding complications, renal injury, and cognitive changes are among the challenges frequently observed with everyday prescribing. Clinicians watch for signs of over-sedation, anticholinergic burden, and drug–drug interactions. See Adverse drug event and Drug interaction for more on safety considerations.

  • Monitoring strategies

    • Regular medication reconciliation, functional assessment, and symptom reviews help detect problems early. In some cases, therapeutic drug monitoring or objective tests may guide adjustments, particularly for drugs with narrow windows or organ dysfunction that affects clearance. See Therapeutic drug monitoring and Medication reconciliation for related topics.

  • Special populations and contexts

    • Dementia care, frailty, and transitions of care (home, hospital, or long-term care facilities) add layers of complexity to safety monitoring. See Delirium and Frailty for connected concepts.

Special considerations in geriatrics

Aging intersects with organ function, cognitive status, living situation, and patient goals, all of which influence pharmacotherapy.

  • Frailty and functional status

    • Frailty modifies risk–benefit calculations, as fragile individuals may experience disproportionate harms or differently weighted benefits from certain drugs. See Frailty.

  • Renal and hepatic function

    • Dose adjustments based on kidney or liver function help prevent accumulation and toxicity. See Renal function and Liver for related topics.

  • Cognitive impairment and behavioral symptoms

    • Dementia and other cognitive disorders complicate adherence, dosing, and monitoring. Clinicians strive to avoid medications that worsen cognition or increase delirium risk when alternatives exist. See Delirium and Dementia.

  • Adherence, formulation, and care setting

    • Simpler regimens, longer-acting formulations when appropriate, and careful care planning improve adherence in primary care and in long-term care settings. See Medication adherence and Long-term care.

  • Pharmacogenomics and precision approaches

    • Genetic variation can influence metabolism and response to certain drugs, offering potential paths to personalize therapy in older adults. See Pharmacogenomics.

Controversies and evolving debates

Geriatric pharmacology navigates several contested areas as clinicians seek to improve outcomes while respecting patient preferences and resource constraints.

  • Balancing safety with access to therapy

    • Critics argue for avoiding over-reliance on rigid criteria that may stigmatize necessary therapies, while proponents emphasize the real-world data showing harm from inappropriate prescribing. The appropriate balance depends on individual goals, comorbidity burden, and life expectancy. See discussions around Beers Criteria and Deprescribing.

  • Under-treatment vs over-treatment

    • Clinicians weigh the risk of undertreating pain, cardiovascular risk, or other conditions against the danger of adverse effects and functional decline. Shared decision-making, patient goals, and functional status are central to these decisions. See Shared decision-making.

  • Evidence gaps and trial representation

    • Older adults, particularly those with frailty or cognitive impairment, are underrepresented in many clinical trials, raising questions about generalizability. Real-world evidence and pragmatic trials increasingly inform practice. See Clinical trials and Geriatric research for related topics.

  • Conceptual critiques of criteria

    • Some critics question whether broad criteria capture individual patient nuance or unintentionally encourage ageism. Proponents argue that criteria are tools to prompt careful evaluation and discussion, not automatic exclusions. See Beers Criteria and START/STOPP criteria.

  • Economic and access considerations

    • Cost, formulary coverage, and access to medications influence prescribing and adherence. Broad policy considerations intersect with clinical decisions, particularly for chronic diseases common in older populations. See Pharmacoeconomics.

See also